MEDICAL POLICY

Medical Policy Title	**Magnetic Resonance Spectroscopy (MRS)**
Policy Number	**6.01.03**
Current Effective Date	March 17, 2025
Next Review Date	January 2026

Our medical policies are based on the assessment of evidence based, peer-reviewed literature, and professional guidelines. Eligibility for reimbursement is based upon the benefits set forth in the member's subscriber contract. (Link to Product Disclaimer)

POLICY STATEMENT(S)

I. Magnetic resonance spectroscopy (MRS) is considered **medically appropriate** when:

   A. Conventional imaging by magnetic resonance imaging (MRI) or computed tomography (CT) provides limited information and **ONE** (1) of the following:

      1. Distinguish recurrent brain tumor from radiation necrosis as an alternative to positron emission tomography (PET);
      2. Diagnosis of certain rare inborn errors of metabolism affecting the Central Nervous System (CNS) (primarily pediatric individuals);
      3. Evidence or suspicion of primary or secondary neoplasm (pretreatment and posttreatment);
      4. Grading of primary glial neoplasm, particularly high-grade versus low-grade glioma;
      5. Evidence or suspicion of brain infection, especially cerebral abscess (pretreatment and posttreatment) and human immunodeficiency virus (HIV)-related infections;
      6. Seizures, especially temporal lobe epilepsy.

II. MRS is considered **investigational** for all other indications.

RELATED POLICIE(S)

Corporate Medical Policy

6.01.29 Positron Emission Tomography (PET) Oncologic Applications

11.01.03 Experimental or Investigational Services

POLICY GUIDELINE(S)

Some indications may be determined by positron emission tomography (PET) or MRS, only one technique (PET or MRS) should be performed, not both.

DESCRIPTION

MRS is a Non-Invasive Procedure used to measure the concentrations of different low molecular weight chemicals within tissues. It is also known as nuclear magnetic resonance (NMR) spectroscopy.

MRS utilizes the same equipment as magnetic resonance imaging (MRI), modified with additional software and hardware, but applies different signals or frequencies to acquire information. In MRI, the frequency is determined by spatial position, whereas, in MRS, the chemical content of the substance scanned determines the frequency. While an MRI provides an anatomic image, MRS provides a functional image related to underlying dynamic physiology. It has become possible to integrate MRS with routine MRI, so that local abnormalities detected by MRI can also be examined biochemically by MRS before and after therapeutic interventions. An MRI image is first generated, and then MRS spectra are developed at the site of interest, termed the voxel.

In normal brain tissue, MRS depicts the following principal spectral peaks: N-acetyl groups, especially N-acetylasparate (NAA); choline-containing compound (Cho), such as a membrane phospholipid (e.g., phosphocholine or glycerophosphocholine); and creatine and phosphocreatine.

MRS has been studied most extensively in a variety of brain pathologies. Different spectral patterns in both healthy and diseased brains are the basis of clinical applications of MRS. MRS findings characteristically associated with non-necrotic brain tumors include elevated Cho levels and reduced NAA levels. Peripheral applications of MRS include the study of myocardial ischemia, peripheral vascular disease, and skeletal muscle. Applications in non-CNS oncologic evaluation have also been explored.

SUPPORTIVE LITERATURE

Although there are studies available regarding MRS, controlled clinical trials are limited. However, small studies have indicated that MRS can change patient management in the determination of cerebral tumor versus abscess or other infectious or inflammatory process, and cerebral tumor versus radiation necrosis. Studies with small sample size and methodological flaws indicate potential future use of MRS for evaluation of prostate cancer, breast cancer, cervical cancer, pancreatic cancer, esophageal cancer, and myocardial ischemia.

Several clinical trials, in various stages, are studying MRS for several indications, including prostate cancer, brain metabolism, breast cancer, and human immunodeficiency virus (HIV).

PROFESSIONAL GUIDELINE(S)

National Comprehensive Cancer Network (NCCN) guidelines Version 3.2024 for Central Nervous System Cancers states:

- MRS may be useful in differentiating tumor from radiation necrosis; maybe helpful in grading tumors or assessing response. The limitations noted are tumors near vessels, air spaces, or bone.

In the 2018 National Institute for Health and Care Excellence (NICE) guideline (NG99), last updated in 2021, brain tumours (primary) and brain metastases in over 16 years of age states:

- Consider advanced MRI techniques, such as MR perfusion and MR spectroscopy, to assess the potential of a high-grade transformation in a tumor appearing to be low grade on standard structural MRI for suspected gliomas.

- Consider advanced MRI techniques, such as MR perfusion, diffusion tensor imaging and MR spectroscopy, if findings from standard imaging are unclear about whether there is recurrence and early identification is potentially clinically useful as a follow up for brain metastases or gliomas.

In 2019 the American College of Radiology (ACR) and American Society of Neuroradiology (ASNR) issued practice parameters for the performance and interpretation of MRS of the central nervous system. The document states that when conventional imaging by MRI or CT provides limited information regarding specific clinical questions, MRS is appropriate for specific indications. The indications include, but is not limited to, grading of primary glial neoplasm, evidence or suspicion of brain infection, seizures.

REGULATORY STATUS

There are no applicable regulatory updates.

CODE(S)

- Codes may not be covered under all circumstances.
- Code list may not be all inclusive (AMA and CMS code updates may occur more frequently than policy updates).
- (E/I)=Experimental/Investigational
- (NMN)=Not medically necessary/appropriate

CPT Codes

Code	Description
76390	Magnetic resonance spectroscopy
0609T (E/I)	Magnetic resonance spectroscopy, determination and localization of discogenic pain (cervical, thoracic, or lumbar); acquisition of single voxel data, per disc, on biomarkers (i.e., lactic acid, carbohydrate, alanine, laal, propionic acid, proteoglycan, and collagen) in at least 3 discs
0610T (E/I)	transmission of biomarker data for software analysis
0611T (E/I)	postprocessing for algorithmic analysis of biomarker data for determination of relative chemical differences between discs
0612T (E/I)	interpretation and report

HCPCS Codes

Code	Description
No code(s)	

ICD10 Codes

Code	Description
C71.0-C71.9	Malignant neoplasm of brain (code range)
C79.31-C79.49	Secondary malignant neoplasm of brain and other parts of the nervous system (code range)
G03.9	Meningitis, unspecified
G04.90	Encephalitis and encephalomyelitis, unspecified
G04.91	Myelitis, unspecified
G06.0	Intracranial abscess and granuloma
G37.4	Subacute necrotizing myelitis of central nervous system
G46.0-G46.8	Vascular syndromes of brain in cerebrovascular diseases (code range)
I67.89	Other cerebrovascular disease
I68.0	Cerebral amyloid angiopathy
I68.8	Other cerebrovascular disorders in diseases classified elsewhere
R56.9	Unspecified convulsions

REFERENCES

American College of Radiology (ACR), American Society of Neuroradiology (ASNR) [Internet]. ACR-ASNR-SPR practice parameter for the performance and interpretation of magnetic resonance spectroscopy of the central nervous system. 2019 [accessed 2024 Nov 19]. Available from: https://www.asnr.org/wp-content/uploads/2021/08/MR-Spectroscopy.pdf

Bissonnette JN, et al. Glutamate and n-acetylaspartate alterations observed in early phase psychosis: a systematic review of proton magnetic resonance spectroscopy studies. Psychiatry Res Neuroimaging. 2022 Apr;321:111459.

Delang N, et al. The effect of contact/collision sport participation without concussion on neurometabolites: A systematic review and meta-analysis of magnetic resonance spectroscopy studies. J Neurochem. 2023 Dec;167(5):615-632.

Eisele A, et al. Magnetic resonance spectroscopy following mild traumatic brain injury: a systematic review and meta-analysis on the potential to detect posttraumatic neurodegeneration. Neurodegener Disease. 2020;20(1):2-11.

Hollingworth W, et al. A systematic literature review of magnetic resonance spectroscopy for the characterization of brain tumors. AJNR Am J Neuroradiol. 2006 Aug;27(7):1404-11.

Krahe J, et al. Neurochemical profiles in hereditary ataxias: a meta-analysis of magnetic resonance spectroscopy studies. Neurosci Biobehav Rev. 2020 Jan;108:854-865.

Liu D, et al. Brain metabolic differences between temporal lobe epileptic seizures and organic non-epileptic seizures in postictal phase: a retrospective study with magnetic resonance spectroscopy. Quant Imaging Med Surg. 2021;11(8):3781-3791.

Murray AJ, et al. Measurement of brain glutathione with magnetic resonance spectroscopy in schizophrenia-spectrum disorders - a systematic review and meta-analysis. Brain Behav Immun. 2023 Sep 26;115:3-12.

Nagashima H, et al. Myo-inositol concentration in MR spectroscopy for differentiating high grade glioma from primary central nervous system lymphoma. Journal of Neuro-Oncology. 2018;136:317-326.

National Comprehensive Cancer Network (NCCN) [Internet]. Clinical Practice Guidelines on Oncology. Central Nervous System Cancers. Version 4.2024. 2025 Jan 21 [accessed 2025 Jan 23]. Available from: https://www.nccn.org/professionals/physician_gls/pdf/cns.pdf

National Institute for Health and Care Excellence (NICE) [Internet]. Brain tumours (primary) and brain metastases in over 16s. Guideline. 2018 July 11. Last updated 2021 Jan 29. [accessed 2025 Jan 23]. Available from: https://www.nice.org.uk/guidance/ng99/chapter/Recommendations

Sciarra A, et al. Value of magnetic resonance spectroscopy imaging and dynamic contrast-enhanced imaging for detecting prostate cancer foci in men with prior negative biopsy. Clin Cancer Res. 2010;16:1875-83.

Targosz-Gajniak MG, et al. Magnetic resonance spectroscopy as a predictor of conversion of mild cognitive impairment to dementia. J Neurol Sci. 2013 Dec 15;335(1-2):58-63.

Thomson AR, et al. Neurometabolite differences in autism as assessed with magnetic resonance spectroscopy: a systematic review and meta-analysis. Neurosci Biobehav Rev. 2024 Jul;162:105728.

Wei B, et al. Feasibility of using magnetic resonance spectroscopy test biomarkers to diagnose Alzheimer's disease: systematic evaluation and meta-analysis. Actas Esp Psiquiatr. 2024 Apr;52(2):161-171.

Zeng H, et al. Correlation between abnormal cellular immune and changes of magnetic resonance spectroscopy in patients with Alzheimer's disease. Neurochem Int. 2024 Jun;176:105737.

CENTERS FOR MEDICARE AND MEDICAID SERVICES (CMS)

Electromagnetic navigation bronchoscopy is not addressed in National or Regional CMS coverage determinations or policies.

SEARCH TERMS

Not Applicable

PRODUCT DISCLAIMER

- Services are contract dependent; if a product does not cover a service, medical policy criteria do not apply.
- If a commercial product (including an Essential Plan or Child Health Plus product) covers a specific service, medical policy criteria apply to the benefit.
- If a Medicaid product covers a specific service, and there are no New York State Medicaid guidelines (eMedNY) criteria, medical policy criteria apply to the benefit.
- If a Medicare product (including Medicare HMO-Dual Special Needs Program (DSNP) product) covers a specific service, and there is no national or local Medicare coverage decision for the service, medical policy criteria apply to the benefit.
- If a Medicare HMO-Dual Special Needs Program (DSNP) product DOES NOT cover a specific service, please refer to the Medicaid Product coverage line.

POLICY HISTORY/REVISION

Committee Approval Dates

10/18/01, 09/19/02, 09/18/03, 07/15/04, 01/05/05, 07/21/05, 05/18/06, 05/17/07, 08/16/07, 06/19/08, 06/18/09, 11/18/10, 11/17/11, 11/15/12, 01/18/24, 01/23/25

Date	Summary of Changes
01/23/25	• Annual review. Policy intent unchanged.
01/01/25	• Summary of changes tracking implemented.
11/18/10	• Policy was made active.
05/27/10	• Policy Deleted.
10/18/01	• Original effective date.